OncoMatch/Clinical Trials/NCT06758375
Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients
Is NCT06758375 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Low-dose teclistamab for multiple myeloma, newly diagnosed.
Treatment: Low-dose teclistamab — This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any treatment for multiple myeloma
History of previous treatment for MM
Cannot have received: allogeneic or autologous hematopoietic cell transplantation
History of allogeneic or autologous hematopoietic cell transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06758375 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages